<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675205</url>
  </required_header>
  <id_info>
    <org_study_id>AGR_2014-33</org_study_id>
    <secondary_id>2014-005720-10</secondary_id>
    <nct_id>NCT02675205</nct_id>
  </id_info>
  <brief_title>Ticagrelor vs Clopidogrel for Platelet Inhibition in Stenting for Cerebral Aneurysm</brief_title>
  <acronym>TIC-TAC</acronym>
  <official_title>Ticagrelor Versus Clopidogrel for Platelet Inhibition in Patients Undergoing Neurovascular Stenting for Intracranial Aneurysm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <brief_summary>
    <textblock>
      Part of interventional neuroradiology procedures for the treatment of selected cerebral&#xD;
      aneurysms are now based on stenting. To reduce thromboembolic events, dual antiplatelet&#xD;
      therapy (APT) combining aspirin and clopidogrel is proposed with close monitoring, since 1/3&#xD;
      of the patients are low responders due to variation of the biological response to clopidogrel&#xD;
      . Ticagrelor is used by few teams but has never been evaluated in a randomized controlled&#xD;
      trial. It could be an option for APT due to more reproducible response with less&#xD;
      interindividual variability and reduced monitoring. The aim of this study is to demonstrate&#xD;
      the interest of ticagrelor for the dual APT for platelet inhibition, in patients undergoing&#xD;
      neurovascular stenting for cerebral aneurysm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">July 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients requiring at least one change of drug or dose adjustment to achieve platlet functional inhibition</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Cerebral Aneurysm</condition>
  <arm_group>
    <arm_group_label>clopidogrel-aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clopidogrel: 75mg and aspirin 250 mg once a day for 15 weeks; prescribed 3 weeks before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ticagrelor-aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor: 90 mg bid and aspirin 250 mg once a day for 15 weeks; prescribed 3 weeks before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>clopidogrel: efficacy and safety in cerebral aneurysm stenting</description>
    <arm_group_label>clopidogrel-aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>ticagrelor:efficacy and safety in cerebral aneurysm stenting</description>
    <arm_group_label>ticagrelor-aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <arm_group_label>clopidogrel-aspirin</arm_group_label>
    <arm_group_label>ticagrelor-aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  unruptured cerebral aneurysm&#xD;
&#xD;
          -  elective endovascular treatment&#xD;
&#xD;
          -  stenting required&#xD;
&#xD;
          -  dual antiplatelet therapy required&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 30, 2015</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

